ArticleDrug design, development and therapy2021
Development and Characterization of PLGA Nanoparticle-Laden Hydrogels for Sustained Ocular Delivery of Norfloxacin in the Treatment of
Article in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- RSM optimization of Tetracycline-loaded PLGA nanoparticles in chitosan/HPMC hydrogels for sustained antibacterial delivery.Scientific reports · 2026Article
- Sustained Ocular Delivery of Moxifloxacin-Ufasomes-Laden In Situ Gel for Keratitis Management.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Mechanisms and Evolution of Antimicrobial Resistance in Ophthalmology: Surveillance, Clinical Implications, and Future Therapies.Antibiotics (Basel, Switzerland) · 2025Review
- Article
- Fagonia indica extract encapsulated in PLGA nanocarriers demonstrated enhanced therapeutic efficacy through improved intracellular uptake of photoactive metabolites.Scientific reports · 2025Article
- Poly lactic-co-glycolic acid enhances the efficacy of the phytomedicine chrysin against cisplatin induced toxicity in submandibular salivary glands.Scientific reports · 2025Article
- Revolutionizing Retinal Therapy: The Role of Nanoparticle Drug Carriers in Managing Vascular Retinal Disorders.Clinical ophthalmology (Auckland, N.Z.) · 2025Review
- Development and Applications of PLGA Hydrogels for Sustained Delivery of Therapeutic Agents.Gels (Basel, Switzerland) · 2024Review
- Article
- Optimizing Nanosuspension Drug Release and Wound Healing Using a Design of Experiments Approach: Improving the Drug Delivery Potential of NDH-4338 for Treating Chemical Burns.Pharmaceutics · 2024Article
- Emphasis on Nanostructured Lipid Carriers in the Ocular Delivery of Antibiotics.Pharmaceutical nanotechnology · 2024Review
- In vitro and in vivo evaluation of dual Clofazimine and Verapamil loaded PLGA nanoparticles.Indian journal of clinical biochemistry : IJCB · 2023Article
- Overview of Antimicrobial Biodegradable Polyester-Based Formulations.International journal of molecular sciences · 2023Review
- Article
- Biomaterials and Extracellular Vesicle Delivery: Current Status, Applications and Challenges.Cells · 2022Review
- Degradable and Non-Degradable Chondroitin Sulfate Particles with the Controlled Antibiotic Release for Bacterial Infections.Pharmaceutics · 2022Article
- Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment.Pharmaceutics · 2022Article
- Development of topical chitosan/ β-glycerophosphate-based hydrogel loaded with levofloxacin in the treatment of keratitis: AnHeliyon · 2022Article
- A Novel Sustained Anti-Inflammatory Effect of Atorvastatin-Calcium PLGA Nanoparticles: In Vitro Optimization and In Vivo Evaluation.Pharmaceutics · 2021Article
- Non-Ionic Surfactants for Stabilization of Polymeric Nanoparticles for Biomedical Uses.Materials (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimNorfloxacin (NFX) has low ocular bioavailability. The current work aimed to develop NFX-loaded nanoparticle (NP)-laden hydrogels to improve the ocular potential of NFX, minimize the need for frequent instillations and lower undesirable side effects.
methodsNFX-loaded NPs were developed via the double-emulsion/solvent evaporation technique, according to 2
resultsThe selected NPs (NP2 and NP6) were spherical in shape and possessed suitable PS (392.02 nm and 190.51 nm) and PDI (0.17 and 0.18), high magnitude of ZP (-30.43 mV and -33.62 mV), high EE% (79.24% and 91.72%), low Q
conclusionG3 and G4 are potential ocular delivery systems for NFX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.